公开(公告)号：US06395786B1

公开(公告)日：2002-05-28

申请号：US09701332

申请日：2000-11-27

申请人： Fumie Sato ,  Tohru Tanami ,  Kazuya Kameo ,  Kenji Yamada ,  Shigeru Okuyama ,  Naoya Ono

发明人： Fumie Sato ,  Tohru Tanami ,  Kazuya Kameo ,  Kenji Yamada ,  Shigeru Okuyama ,  Naoya Ono

IPC分类号： A01N3708

CPC分类号： A61K31/5575 ,  A61K31/557 ,  C07C405/00 ,  Y10S514/923

摘要： A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z is an ethylene group, a trans-vinylene group, OCH2 or S(O)nCH2, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 3, and n is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.

摘要翻译： 一种睡眠诱导制剂，其包含作为有效成分的由下式表示的前列腺素衍生物：其中X是卤素原子，Y是由（CH 2）m表示的基团，顺式亚乙烯基或亚苯基，Z是 亚乙基，反亚乙烯基，OCH 2或S（O）n CH 2，R 1是C 3-10环烷基，被C 1-4烷基取代的C 3-10环烷基，C 4-13环烷基烷基， C5-10烷基，C5-10烯基，C5-10炔基或桥连环烃基，R2是氢原子，C1-10烷基或C3-10环烷基，m是 1〜3的整数，n为0,1或2，其药学上可接受的盐或其水合物。

公开(公告)号：US06191291B1

公开(公告)日：2001-02-20

申请号：US09456413

申请日：1999-12-08

申请人： Fumie Sato

发明人： Fumie Sato

IPC分类号： C07D30300

CPC分类号： C07C69/738 ,  C07C405/00 ,  C07C2601/10 ,  C07F7/1804 ,  Y02P20/55

摘要： A substituted cyclopentene derivative of the formula (VII): wherein R is a hydrogen atom, alkyl radical having 1 to 6 carbon atoms, alkenyl radical having 2 to 6 carbon atoms, alkynyl radical having 2 to 6 carbon atoms, cycloalkyl radical having 3 to 8 carbon atoms, aralkyl radical having 7 to 19 carbon atoms, aryl radical having 6 to 12 carbon atoms, alkoxy radical having 1 to 6 carbon atoms, alkenyloxy radical having 2 to 6 carbon atoms, alkylthio radical having 1 to 6 carbon atoms or alkenylthio radical having 2 to 6 carbon atoms; X1 is (&agr;-OZa, &bgr;-H) or (&agr;-H, &bgr;-OZa), X3 is (&agr;-OZd, &bgr;-H), (&agr;-H, &bgr;-OZd) or oxygen atom, each of Za and Zd, which may be the same or different, is a hydrogen atom or a protective radical for a hydroxyl radical.

摘要翻译： 式（VII）的取代环戊烯衍生物：其中R是氢原子，具有1-6个碳原子的烷基，具有2-6个碳原子的烯基，具有2-6个碳原子的炔基，具有3-8个碳原子的环烷基 碳原子数为7〜19的芳烷基，碳原子数为6〜12的芳基，碳原子数1〜6的烷氧基，碳原子数2〜6的烯氧基，碳原子数1〜6的烷硫基，烯基硫基 具有2至6个碳原子; X1是（α-OZa，β-H）或（α-H，β-OZa），X3是（α-OZd，β-H），（α-H，β-OZd） 或氧原子，Za和Zd各自可以相同或不同，是氢原子或羟基的保护基。

公开(公告)号：US5874634A

公开(公告)日：1999-02-23

申请号：US894879

申请日：1997-09-02

申请人： Fumie Sato

发明人： Fumie Sato

IPC分类号： C07C69/738 ,  C07C405/00 ,  C07F7/18 ,  C07C47/597

CPC分类号： C07C69/738 ,  C07C405/00 ,  C07F7/1852 ,  C07F7/1856 ,  C07C2101/10 ,  Y02P20/55

摘要： A halogenated substituted cyclopentene derivative of formula (I): ##STR1## wherein R is a hydrogen atom, alkyl radical having 1-6 carbon atoms, alkenyl radical having 2-6 carbon atoms, alkynyl radical having 2-6 carbon atoms, cycloalkyl radical having 3-8 carbon atoms, aralkyl radical having 7-19 carbon atoms, aryl radical having 6-12 carbon atoms, alkoxy radical having 1-6 carbon atoms, alkenyloxy radical having 2-6 carbon atoms, alkylthio radical having 1-6 carbon atoms or alkenylthio radical having 2-6 carbon atoms; X.sup.1 is (.alpha.-OZ.sup.a, .beta.-H) or (.alpha.-H, .beta.-OZ.sup.a), X.sup.3 is (.alpha.-OZ.sup.d, .beta.-H), (.alpha.-H, .beta.-OZ.sup.d) or oxygen atom, each of Z.sup.a and Z.sup.d, which may be the same or different, is a hydrogen atom or a protective radical for a hydroxyl radical; and W is a halogen atom.

摘要翻译： PCT No.PCT / JP96 / 00422 Sec。 371日期：1997年9月2日 102（e）1997年9月2日PCT PCT 1996年2月23日PCT公布。 WO96 / 26891 PCT出版物 日本1996年9月6日一种式（I）的卤代取代环戊烯衍生物：其中R是氢原子，具有1-6个碳原子的烷基，具有2-6个碳原子的烯基， 2-6个碳原子，具有3-8个碳原子的环烷基，具有7-19个碳原子的芳烷基，具有6-12个碳原子的芳基，具有1-6个碳原子的烷氧基，具有2-6个碳原子的烯氧基 具有1-6个碳原子的烷硫基或具有2-6个碳原子的烯基硫基; X1是（α-Za，β-H）或（α-H，β-OZa），X3是（α-Zd，β-H），（α-H，β-OZd）或氧原子 和Zd可以相同或不同，是氢原子或羟基的保护基; W是卤素原子。

公开(公告)号：US5583158A

公开(公告)日：1996-12-10

申请号：US416871

申请日：1995-04-19

申请人： Fumie Sato ,  Takehiro Amano ,  Kazuya Kameo ,  Tohru Tanami ,  Masaru Mutoh ,  Naoya Ono ,  Jun Goto

发明人： Fumie Sato ,  Takehiro Amano ,  Kazuya Kameo ,  Tohru Tanami ,  Masaru Mutoh ,  Naoya Ono ,  Jun Goto

IPC分类号： A61K31/557 ,  C07C405/00

CPC分类号： C07C405/0025 ,  C07C405/0033

摘要： A prostaglandin E.sub.1 analogue represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; and X is an oxygen atom and R.sup.2 represents ##STR2## or X is a sulfur atom and R.sup.2 represents ##STR3## The compound has a strong and prolonged inhibitory action for platelet aggregation and is useful for treatment of various thrombotic diseases including peripheral circulatory disturbance.

摘要翻译： PCT No.PCT / JP93 / 01510 Sec。 371日期1995年04月19日 102（e）日期1995年4月19日PCT提交1993年10月20日PCT公布。 公开号WO94 / 08961 日本1994年4月28日由式表示的前列腺素E1类似物，其中R1表示氢原子或C1-C6烷基; X是氧原子，R2表示或或X是硫原子，R2代表血小板聚集的作用，可用于治疗各种血栓形成疾病，包括外周循环障碍。

公开(公告)号：US5049681A

公开(公告)日：1991-09-17

申请号：US216336

申请日：1988-07-08

申请人： Fumie Sato

发明人： Fumie Sato

IPC分类号： C07C59/42 ,  C07F7/08 ,  C07F7/18 ,  C07F7/22 ,  C07D309/04 ,  C07C33/04

CPC分类号： C07F7/0814 ,  C07C59/42 ,  C07F7/0818 ,  C07F7/1852 ,  C07F7/2212

摘要： A novel optically active allyl alcohol derivative represented by the following general formulae (I), (II), (III) and (IV): ##STR1## The novel optically active allyl alcohol can be used effectively for producing leucotrienes B.sub.4 by the process of reacting an optically active halogen substituted allyl alcohol and a novel optically active acetylene-substituted allyl alcohol.

公开(公告)号：US5037855A

公开(公告)日：1991-08-06

申请号：US437886

申请日：1989-11-17

申请人： Fumie Sato

发明人： Fumie Sato

IPC分类号： C07C33/42 ,  C07C33/44 ,  C07C33/48 ,  C07D303/48 ,  C07F7/08 ,  C07F7/22

CPC分类号： C07C33/483 ,  C07C33/423 ,  C07C33/44 ,  C07D303/48 ,  C07F7/0814 ,  C07F7/0818 ,  C07F7/2212

摘要： Provided herein is an optically active alcohol having a silyl group, stannyl group, or halogen atom at the .gamma.-position, selected from compounds represented by the general formula [I], ##STR1## the general formula [II], ##STR2## the general formula [III], ##STR3## and the general formula [IV], ##STR4## (where, R denotes a C.sub.1 -C.sub.10 substituted or unsubstituted alkyl group or substituted or unsubstituted phenyl group; A denotes a silyl group represented by ##STR5## a stannyl group represented by ##STR6## or a halogen atom. R.sup.1, R.sup.2, and R.sup.3 are substituted or unsubstituted C.sub.1 -C.sub.10 alkyl groups or substituted or unsubstituted phenyl group, which may be the same or different, provided that this does not apply in the case where A represents a stannyl group or halogen atom in the general formulas [III] and [IV].); a process for producing the same, and a process for resolving the optically active alcohol into isomers of high optical purity.

公开(公告)号：US4987236A

公开(公告)日：1991-01-22

申请号：US437885

申请日：1989-11-17

申请人： Fumie Sato

发明人： Fumie Sato

IPC分类号： C07C33/42 ,  C07C33/44 ,  C07C33/48 ,  C07D303/48 ,  C07F7/08 ,  C07F7/22

CPC分类号： C07C33/483 ,  C07C33/423 ,  C07C33/44 ,  C07D303/48 ,  C07F7/0814 ,  C07F7/0818 ,  C07F7/2212

摘要： Provided herein is an optically active alcohol having a silyl group, stannyl group, or halogen atom at the .gamma.-position, selected from compounds represented by the general formula [I], ##STR1## the general formula [II], ##STR2## the general formula [III], ##STR3## and the general formula [IV], ##STR4## (where, R denotes a C.sub.1 -C.sub.10 substituted or unsubstituted alkyl group or substituted or unsubstituted phenyl group; A denotes a silyl group represented by ##STR5## a stannyl group represented by ##STR6## or a halogen atom, R.sup.1, R.sup.2, and R.sup.3 are substituted or unsubstituted C.sub.1 -C.sub.10 alkyl groups or substituted or unsubstituted phenyl group, which may be the same or different, provided that this does not apply in the case where A represents a stannyl group or halogen atom in the general formulas [III] and [IV].); a process for producing the same, and a process for resolving the optically active alcohol into isomers of high optical purity.

公开(公告)号：US20100256113A1

公开(公告)日：2010-10-07

申请号：US12680301

申请日：2008-09-25

申请人： Kenichi Onda ,  Kenichiro Imamura ,  Fumie Sato ,  Hiroyuki Moritomo ,  Yasuharu Urano ,  Yuki Sawada ,  Naoki Ishibashi ,  Keita Nakanishi ,  Kazuhiro Yokoyama ,  Shigetada Furukawa ,  Kazuhiro Momose

发明人： Kenichi Onda ,  Kenichiro Imamura ,  Fumie Sato ,  Hiroyuki Moritomo ,  Yasuharu Urano ,  Yuki Sawada ,  Naoki Ishibashi ,  Keita Nakanishi ,  Kazuhiro Yokoyama ,  Shigetada Furukawa ,  Kazuhiro Momose

IPC分类号： A61K31/4709 ,  C07D215/233 ,  C07D405/12 ,  C07D401/12 ,  C07D413/12 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4725 ,  A61K31/55 ,  A61K31/553

CPC分类号： C07D401/12 ,  C07D215/233 ,  C07D401/06 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/107

摘要： As a result of extensive studies on NAD(P)H oxidase inhibitors, the present inventors found that a quinolone derivative having, at the 2-position, an alkyl group substituted with a heteroatom or the like has an excellent NAD(P)H oxidase inhibitory activity, and accomplished the present invention. The compound of the present invention has a reactive oxygen species production inhibitory activity based on the NAD(P)H oxidase inhibitory activity, and therefore can be used as an agent for preventing and/or treating diabetes, impaired glucose tolerance, hyperlipidemia, fatty liver, diabetic complications and the like.

摘要翻译： 作为对NAD（P）H氧化酶抑制剂的广泛研究的结果，本发明人发现，在2位具有被杂原子等取代的烷基的喹诺酮衍生物具有优异的NAD（P）H氧化酶 抑制活性，完成了本发明。 本发明的化合物具有基于NAD（P）H氧化酶抑制活性的活性氧产生抑制活性，因此可用作糖尿病预防和/或治疗药物，糖耐量异常，高脂血症，脂肪肝 ，糖尿病并发症等。

公开(公告)号：US20070176164A1

公开(公告)日：2007-08-02

申请号：US10591950

申请日：2005-03-08

申请人： Fumie Sato ,  Yuuki Takayama

发明人： Fumie Sato ,  Yuuki Takayama

IPC分类号： C09K11/06 ,  H01L51/54

CPC分类号： C07C217/80 ,  C07C211/54 ,  C07D213/53 ,  C07D213/65 ,  C07D213/85 ,  C07D333/16 ,  C07D333/24 ,  C07D495/04 ,  C07F7/081 ,  C09K11/06 ,  C09K2211/14 ,  H01L51/0051 ,  H01L51/0059 ,  H01L51/0067 ,  H01L51/0068 ,  H01L51/0071 ,  H01L51/5012 ,  H05B33/14 ,  Y10S428/917

摘要： A π-conjugated aromatic ring-containing compound represented by the formula (1) below is relatively stable and useful as a light-emitting material for light from blue-violet region to red region. [In the formula, R1-R6 independently represent a hydrogen atom or the like; A and D independently represent a pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, furan ring, pyrrole ring, pyrazole ring, imidazole ring, thiophene ring, benzothiadiazole ring, thieno[3,4-b]pyrazine ring, furo[3,4-b]pyrazine ring, 6H-pyrrolo[3,4-b]pyrazine ring or the like; a1, a2 and a3 independently represent 0 or 1; and n1 and n2 independently represent an integer of 1-5.]

摘要翻译： 由下式（1）表示的π-共轭芳环化合物作为用于从蓝紫色区域到红色区域的光的发光材料是相对稳定和有用的。 [式中，R 1〜R 6独立地表示氢原子等; A和D独立地表示吡啶环，嘧啶环，哒嗪环，吡嗪环，呋喃环，吡咯环，吡唑环，咪唑环，噻吩环，苯并噻二唑环，噻吩并[3,4-b]吡嗪环，呋喃并[3 ，4-b]吡嗪环，6H-吡咯并[3,4-b]吡嗪环等; 一个<！ - SIPO - > 1 2 和3 <3>独立地代表0或1; 且n 1和n 2独立地表示1-5的整数。]

公开(公告)号：US20050009917A1

公开(公告)日：2005-01-13

申请号：US10493693

申请日：2003-08-07

申请人： Fumie Sato ,  Iwai Arai ,  Norikazu Takano ,  Tohru Tanami ,  Makoto Yagi

发明人： Fumie Sato ,  Iwai Arai ,  Norikazu Takano ,  Tohru Tanami ,  Makoto Yagi

IPC分类号： A61K31/5575 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P27/02 ,  A61P37/08 ,  A61K31/557

CPC分类号： A61K31/5575 ,  Y10S514/861 ,  Y10S514/887

摘要： A pharmaceutical preparation for preventing or treating pruritic symptoms which contains as an effective ingredient a prostaglandin derivative represented by formula [1] wherein X1 and X2 which are different from each other represent a hydrogen atom, a halogen atom or a hydroxyl group; Y is an ethylene group, a vinylene group or an ethynylene group; Z is the formula (CH2)kA(CH2)hB(CH2)q, (CH2)kA(CH2)rA′(CH2)t (CH2)kB(CH2)hB′(CH2)q or (CH2)k-1B′(CH2)q-1A′wherein k is an integer of 1 to 4, h is an integer of 0 to 4, q is an integer 1 to 4, r is an integer of 0 to 4, and t is an integer of 0 to 2; A and A′ which may be the same or different represent an ethylene group, a vinylene group or an ethynylene group; B and B′ which may be the same or different represent an oxygen atom or a group represented by the formula S(O)u wherein u is an integer of 0 to 2; W1 is a hydroxyl group, a C1-10 alkyloxy group, a C3-10 cycloalkyloxy group, an aryloxy group or an arylalkyloxy group; W2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s), or a group represented by the formula wherein W4 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group or a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s); v is an integer of 0 to 4; W3 is a hydrogen atom or a methyl group, or W3 when taken together with W2 and the adjacent carbon atom forms a C3-10 cycloalkyl group; m is 0 or 1, a pharmaceutically acceptable salt thereof or a hydrate thereof.

摘要翻译： 用于预防或治疗瘙痒症状的药物制剂，其含有作为有效成分的由式[1]表示的前列腺素衍生物，其中X 1和X 2彼此不同，表示氢原子，卤素原子或 羟基; Y是亚乙基，亚乙烯基或亚乙炔基; Z是式（CH2）kA（CH2）hB（CH2）q，（CH2）kA（CH2）rA'（CH2）t（CH2）kB（CH2）hB'（CH2）q或（CH2） '（CH 2）q-1A'其中k为1〜4的整数，h为0〜4的整数，q为1〜4的整数，r为0〜4的整数，t为 0〜2; A和A'可以相同或不同，表示亚乙基，亚乙烯基或亚乙炔基; B和B'可以相同或不同，表示氧原子或由式S（O）u表示的基团，其中u为0-2的整数; W 1是羟基，C 1-10烷氧基，C 3-10环烷氧基，芳氧基或芳基烷氧基; W 2是C 1-10烷基，C 2-10烯基，C 2-10炔基，C 3-10环烷基，被C 3-10环烷基取代的C 1-5烷基， 或由下式表示的基团，其中W 4是C 1-10烷基，C 2-10烯基，C 2-10炔基或被C 3-10环烷基取代的C 1-5烷基， ; v为0〜4的整数; W 3为氢原子或甲基时，W 3与W 2一起形成，相邻碳原子形成C3-10环烷基; m为0或1，其药学上可接受的盐或其水合物。